BioNano Genomics Inc Stock Price Target Forecast, (BNGO) Prediction 2022, 2023, 2025, 2030

January 6, 2022.

Unlocking Growth Potential for Bionano Genomics Inc. (NASDAQ: BNGO)

There have been no upward or downward revisions for the firm in the previous seven days, which might be a good sign for gaining insight into short-term price volatility. We can see that BNGO’s technical picture reveals that short-term indications indicate that the stock is on average a 100 percent sell. Medium-term indications, on the other hand, have categorised the stock as a 100 percent sell, while long-term indicators, on average, have indicated that it is a 100 percent sell.

On a scale of 1.00 to 5.00, 4 analyst(s) have provided their ratings on the stock’s projected evaluation, indicating a strong buy to a strong sell recommendation. BNGO stock is rated as a Hold by 0 analyst(s), Buy by 4 analysts, and Overweight by 0 analysts. Meanwhile, 0 analyst(s) rate the stock as Underweight, while 0 rate it as a Sell. Since a result, investors who want to grow their holdings of the company’s stock will be able to do so, as the stock’s average rating is Buy.

The PEG ratio for BNGO is roughly 0, according to technical analysis, with the company now trading nearly -14.67 percent and -32.67 percent away from the simple moving averages for 20 and 50 days, respectively. The Relative Strength Index (RSI, 14) is now at 32.01, while the 7-day volatility ratio is at 9.61 percent, and the 30-day volatility ratio is at 8.02 percent. The average true range (ATR) of Bionano Genomics Inc. (BNGO) is 0.27. Over the next 52 weeks, the company’s stock is expected to trade at an average price of $12.00, with a low of $10.00 and a high of $14.00. According to these price projections, the low is -259.71 percent below current price, while the yearly goal high requires a move of -403.6 percent. Furthermore, investors are likely to embrace analysts’ consensus price of $12.00 because it represents a -331.65% reduction from current levels.

stocksregister.com is the source of this information.


December 20, 2021

Analysis of Bionano Genomics Inc. (BNGO)

Bionano Genomics Inc.’s stock has outperformed the relevant industry, according to data. The stock has dropped 52.91 percent in the last six months, with a growth rate of 12.82 percent this year, compared to 7.10 percent for the industry. Aside from that, the firm has raised its sales growth forecast for the fiscal year 2021. The current quarter’s growth is expected to be 25.00 percent, while the following quarter’s growth is expected to be -20.00 percent. The revenue growth from the previous fiscal year is expected to be 91.60 percent.

The average revenue prediction for the current quarter is $4.23 million, according to four analysts who provided projections. For the quarter ending in December 2021, 4 expects to earn $5.05 million in revenue. For this quarter and the next, sales were $2.2 million and $3.99 million, respectively, a year ago, and analysts estimate sales to increase by 92.60 percent for the current quarter and 26.60 percent for the next.

marketingsentinel.com is the source of this information.


December 10, 2021.

Do Options Traders Know Something We Don’t About Bionano (BNGO)?

Based on recent changes in the options market, Bionano Genomics, Inc. BNGO investors should pay close attention to the stock. Because the Feb 18, 2022 $5.00 Call had among of the greatest implied volatility of all stock options today, it was a good bet.

What Do Analysts Believe?

Options traders are clearly pricing in a huge increase for Bionano shares, but what is the company’s underlying picture? Bionano is now ranked #4 (Sell) in the Medical – Biomedical and Genetics category, which is in the Bottom 37% of our Zacks Industry Rank. No analyst has raised their earnings expectations for the current quarter in the previous 60 days, while one has reduced the estimate lower. As a result, our Zacks Consensus Estimate for the current quarter has expanded from a loss of 7 cents per share to a loss of 24 cents.

Given the current sentiment toward Bionano among analysts, this high implied volatility might indicate the emergence of a trade. Options traders frequently seek for options with high implied volatility to sell premium. Many seasoned traders employ this method because it captures decay. The goal for these traders at expiry is that the underlying stock does not move as much as projected.

nasdaq.com is the source for this information.


December 6, 2021

To meet the consensus price target, Bionano Genomics Inc. is expected to drop -326.83 percent.

As witnessed at the close of recent trade, BNGO was immediately in the red. The performance over the last five days has been red, with action -15.00 percent. The stock’s daily price was reduced by -3.68 percent after it fell to weekly highs of 4.03 on Friday, 12/03/21. The company’s stock has gained 10.39 percent year to date, with a 5-day performance of -15.00 percent in the negative. Bionano Genomics Inc. (NASDAQ:BNGO) is down 44.44 percent in the 30-day time frame. We can observe that 37.5 million shares were sold at a short interest cover duration of 4.12 days when we look at the short shares.

Wall Street analysts’ consensus price objective for the company is $12.00, implying a 72.67 percent increase from its present market value for bulls. According to analyst estimates, BNGO’s anticipated low is $10.00, with a target high of $14.00. The stock would have to drop -326.83 percent from its present position to reach the anticipated high, while it would have to rise -204.88 percent to reach the expected low.

Estimates and projections from Bionano Genomics Inc. (BNGO).

The stock of Bionano Genomics Inc. is performing far better than most of its rivals in the same industry, according to data. According to the numbers, the company’s stock has dropped 59.52 percent in the last six months, representing a 12.82 percent annual growth rate that is much greater than the industry average of 7.30 percent. Furthermore, analysts have raised revenue predictions for fiscal year 2021, indicating that stronger expectations are expected. The rating companies expect that Bionano Genomics Inc.’s sales will increase by 25.00 percent in the current quarter, but will decline by -20.00 percent in the next quarter. Year-over-year growth is expected to be 91.60 percent higher than the previous fiscal year.

According to consensus forecasts from four financial experts, the company’s sales in the current quarter will be $4.23 million on average. Bionano Genomics Inc.’s sales for the quarter ending December 2021 is expected to be $5.05 million, according to 4 analysts. The company’s sales in the previous quarters was $2.2 million and $3.99 million, respectively. Experts expect the company’s current quarter revenues to increase by 92.60 percent, according to analysts. Sales growth is expected to be 26.60 percent in the coming quarter, according to forecasts.

marketingsentinel.com is the source of this information.


October 19, 2021

BNGO Stock Price Prediction 2021, 2022, 2025, and 2030 – BNGO Stock Forecast 2021

Small-cap stocks may reward investors with substantially better returns than established firms — at the cost of a far higher level of risk. Bionano Genomics (BNGO), one of the most anticipated small-cap stocks this year, is ready to skyrocket in the months ahead.

We’ll go through our BNGO Stock Forecast in depth in this post. We’ll go through what BNGO is and what the stock’s future prospects are before pointing you where you can purchase BNGO right now – with no commissions! Stock Price Predictions for BNGO in 2021 and 2022

The greatest stocks to buy right now are usually ones that are in the growth stage of their lifecycle yet have solid fundamentals to back up any possible investment. Bionano Genomics (BNGO) fits this description perfectly, and they want to develop their business in the future year. Let’s take a look at what Bionano Genomics does and what the future holds for the BNGO stock price.

Bionano Genomics Inc is a San Diego-based pharmaceutical firm that develops technologies for genomic analysis. The importance of genomic analysis in diagnosing disorders and enhancing treatment efficacy is one of the reasons why BNGO’s services are so well respected in the healthcare business. Erik Holmlin is the current CEO of BNGO, which is a publicly traded business on the NASDAQ.

Now let’s look at the long-term picture. Small-cap companies appeal to investors with a long-term investing perspective because they have the potential to generate extraordinary profits. However, because there are so many to pick from, it’s critical to conduct due research and arrive at a logical stock value.

In the instance of BNGO, the firm appears to be more appealing in the long term than it is in the near term.

According to Investing.com, analysts at Oppenheimer & Co, one of the industry’s premier equities research firms, have maintained a buy recommendation on BNGO with a $14 price objective. If the price rises to this level, it would have increased by a whopping 171 percent!

The FDA’s approval of the Saphyr technology for use in commercial settings might be beneficial to Bionano Genomics. Because they are not authorised to sell to insurers or other healthcare firms, BNGO’s target clientele is now confined to research institutes. If the firm can demonstrate the system’s safety and effectiveness, we could see some improvements in this area in the next year or two, allowing BNGO to fulfil its full potential.

economywatch.com is the source of this information.


Disclaimer: The views and investment tips expressed by investment expert on Stock consultant bihar are Sourced From Brokerage Firms Research Reports & Market Experts Opinion. We advises users to consult your investment advisor before taking any decisions. Our Website Contain Demat Account & Algo Trading affliate Link. If You’ll Register Through Our Link We May Get Profit.

More Share Price Target Updates:

We will be happy to hear your thoughts

Leave a reply

Stock Consultant Bihar
Logo